Journal of Clinical Microbiology

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

Retrieved on: 
Wednesday, March 20, 2024
Sepsis, Development, Lyme disease, Growth, Panel, International, Laboratory, Instrument, LDT, ASPR, Journal of Clinical Microbiology, Pharmaceutical industry

LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates.

Key Points: 
  • LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates.
  • The Company is currently in discussions with potential LDT partners and plans to provide early Lyme disease results to U.S. reference laboratories nationwide.
  • Engaged Dr. Robin Robinson as a strategic advisor to aid in commercialization of the T2Biothreat Panel.
  • A live and recorded webcast of the call will be available on the “Investors” section of the Company’s website at www.t2biosystems.com .

TGV-Dx Announces Study Results Showing AtbFinder as Novel Paradigm for Rapid Antibiotic Susceptibility Testing for Multidrug-Resistant Infections

Retrieved on: 
Thursday, March 2, 2023
Urinary tract infection, Sepsis, Cystic fibrosis, Hospital, 3D, Journal, Patient, Infection, Pseudomonas aeruginosa, Journal of Clinical Microbiology, Biology, Cell, Physician, Pharmaceutical industry

The study on the advanced test system for optimal antibiotic therapy for people with severe pulmonary infections was published in the Journal of Clinical Microbiology .

Key Points: 
  • The study on the advanced test system for optimal antibiotic therapy for people with severe pulmonary infections was published in the Journal of Clinical Microbiology .
  • AtbFinder is fundamentally different from other antimicrobial susceptibility tests as it, for the first time, selects antibiotics that target the entire bacterial community.
  • “AtbFinder is a new era in antimicrobial susceptibility testing that can potentially save thousands of lives and reduce healthcare costs.
  • “We are very excited that AtbFinder based on novel principles for antibiotic selection demonstrated such groundbreaking results,” said Victor Tetz, a scientific founder of the project.

Molecular LIMS Leader Launches Ovation Research Network

Retrieved on: 
Tuesday, July 12, 2022
Data Management, Biotechnology, Technology, Professional Services, Health, Research, Infectious Diseases, Data Analytics, Software, Genetics, Science, Cloud, Prevalence, Acceleration, Laboratory information management system, Journal of Clinical Microbiology, LIMS, Severe acute respiratory syndrome coronavirus 2, Patient, Network, COO, Research, COVID-19, Population, Doctor of Philosophy, VTF, National, Software, Tech, Pharmaceutical industry

Cloud-based molecular Laboratory Information Management Software (LIMS) leader Ovation today announced the formal launch of the Ovation Research Network.

Key Points: 
  • Cloud-based molecular Laboratory Information Management Software (LIMS) leader Ovation today announced the formal launch of the Ovation Research Network.
  • The Ovation Research Network is a platform of clinical laboratories who use Ovations LIMS solution and also contribute consented biospecimens for research purposes.
  • Ovation Research Network labs contributing to the platform look forward to whats ahead.
  • Lisa Justesen, COO of Soft Cell Labs, said: We are excited for the opportunity to directly contribute to timely and important research through our participation in the Ovation Research Network.

Vietnam leads the way with SOS Stool Method to diagnose TB

Retrieved on: 
Thursday, October 28, 2021
Sputum, Tuberculosis, Research, Diagnosis, Pediatrics, Disease, Method, Stomach, KNCV, NTP, GeneXpert MTB/RIF, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Child, Union, Journal of Clinical Microbiology, Nose, SOS, Mark R. Dybul, Margaret Chan, Time, Conference, TB, Simple, WHO, Health in Vietnam, GLOBE, Parent, Journal, HIV, Mouth, Vaccine, Medical device, Furniture

Vietnam, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vietnam is the first country in the world to routinely use an innovative method to diagnose tuberculosis (TB) using stool.

Key Points: 
  • Vietnam, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Vietnam is the first country in the world to routinely use an innovative method to diagnose tuberculosis (TB) using stool.
  • The Pediatric TB Operational Sustainability Expertise Exchange (POSEE) Taskforce also describes the benefits of using stool to diagnose TB.As the SOS Stool Method is published in the peer reviewed Journal of Clinical Microbiology , many other countries are expected to follow Vietnams example and use this method.
  • Extended research such as head-to-head comparisons with other stool processing methods (FIND and TB Speed study) and the cost effectiveness of the SOS Stool Method (SOS-TBIM study) - have since be done.
  • Thao: The SOS Stool Method made my sons diagnosis and treatment much more accurate and easier.

Hardy Diagnostics Presents: Detection of Carbapenemase Producing Organisms; Advancements and Barriers to the Clinical Laboratory

Retrieved on: 
Tuesday, September 21, 2021
CRE, LFS, Molecular diagnostics, Medical college, Partnership, Medical College of Wisconsin, American Society for Microbiology, Froedtert Hospital, CST, Medical director, Patient, Bacteria, Journal of Clinical Microbiology, Family, Hardy Diagnostics, Journal, Pathology, AAM, Doctor of Philosophy, Society, GLOBE, Medical device, Medical imaging

Some bacteria in this family are resistant to nearly all antibiotics, leaving only more toxic or less effective treatment options.

Key Points: 
  • Some bacteria in this family are resistant to nearly all antibiotics, leaving only more toxic or less effective treatment options.
  • To learn more about the utility of screening for Carbapenem-resistant Enterobacterales and the technologies that are available to do so, Hardy Diagnostics is pleased to offer a free webinar titled, "Detection of carbapenemase-producing organisms; advancements and barriers to the clinical lab," on Oct.7, 2021, at 11 a.m. PST/1 p.m. CST.
  • Led by Nathan Ledeboer, PhD, D(ABMM), F(AAM) this discussion will:
    Discuss the utility of screening for CRE from clinical specimens.
  • To learn more about the products offered at Hardy Diagnostics to detect and diagnose disease, please visit www.hardydiagnostics.com .